Purple Biotech Stock Fundamentals
| PPBT Stock | ILA 4.80 0.20 4.00% |
Purple Biotech fundamentals help investors to digest information that contributes to Purple Biotech's financial success or failures. It also enables traders to predict the movement of Purple Stock. The fundamental analysis module provides a way to measure Purple Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Purple Biotech stock.
Purple |
Purple Biotech Company Return On Equity Analysis
Purple Biotech's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Purple Biotech Return On Equity | -0.39 |
Most of Purple Biotech's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Purple Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Purple Biotech has a Return On Equity of -0.3879. This is 98.38% lower than that of the Healthcare sector and 98.94% lower than that of the Biotechnology industry. The return on equity for all Israel stocks is 25.13% higher than that of the company.
Purple Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Purple Biotech competition to find correlations between indicators driving Purple Biotech's intrinsic value. More Info.Purple Biotech is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Purple Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Purple Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Purple Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Purple Biotech's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Purple Biotech could also be used in its relative valuation, which is a method of valuing Purple Biotech by comparing valuation metrics of similar companies.Purple Biotech is rated below average in return on equity category among its peers.
Purple Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | (5 M) | |||
| Shares Outstanding | 205.98 M | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 56.01 X | |||
| Gross Profit | (55 K) | |||
| EBITDA | (21.43 M) | |||
| Net Income | (21.67 M) | |||
| Cash And Equivalents | 48.39 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 804 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 14.30 X | |||
| Book Value Per Share | 0.26 X | |||
| Cash Flow From Operations | (16.73 M) | |||
| Earnings Per Share | (0.11) X | |||
| Beta | 1.51 | |||
| Market Capitalization | 134.51 M | |||
| Total Asset | 54.62 M | |||
| Net Asset | 54.62 M |
About Purple Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Purple Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Purple Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Purple Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel. PURPLE BIOTECH operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 13 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.